Terms: = Liver cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Clinical Outcome
49 results:
1. A Lactic Acid Metabolism-Related Gene Signature for Predicting clinical outcome and Tumor Microenvironmental Status in Patients with Hepatocellular Carcinoma.
Zhou Z; Wu B; Chen J; Shen Y; Wang J; Chen X; Fei F; Zhu M
Nutr Cancer; 2024; 76(3):279-295. PubMed ID: 38226887
[TBL] [Abstract] [Full Text] [Related]
2. Development and evaluation of a risk score model based on a WNT score gene-associated signature for predicting the clinical outcome and the tumour microenvironment of hepatocellular carcinoma.
Li P; Ma X; Huang D; Gu X
Int J Immunopathol Pharmacol; 2023; 37():3946320231218179. PubMed ID: 38054921
[No Abstract] [Full Text] [Related]
3. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
4. Identification and validation of a cancer-associated fibroblasts-related scoring system to predict prognosis and immune landscape in hepatocellular carcinoma through integrated analysis of single-cell and bulk RNA-sequencing.
Bao L; Zhang X; Wang W; Jiang B
Aging (Albany NY); 2023 Oct; 15(20):11092-11113. PubMed ID: 37857017
[TBL] [Abstract] [Full Text] [Related]
5. 10 years, 100 robotic major hepatectomies: a single-center experience.
McCarron F; Cochran A; Ricker A; Mantha R; Driedger M; Beckman M; Vrochides D; Martinie J
Surg Endosc; 2024 Feb; 38(2):902-907. PubMed ID: 37845533
[TBL] [Abstract] [Full Text] [Related]
6. A novel nomogram based on the hematological prognosis risk scoring system can predict the overall survival of patients with hepatocellular carcinoma.
Lei K; Deng Z; Wang J; Wang H; Hu R; Li Y; Wang X; Xu J; You K; Liu Z
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14631-14640. PubMed ID: 37584710
[TBL] [Abstract] [Full Text] [Related]
7. setD1A drives stemness by reprogramming the epigenetic landscape in hepatocellular carcinoma stem cells.
Chen J; Xu Z; Huang H; Tang Y; Shan H; Xiao F
JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37581938
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic value of the S100 calcium-binding protein family members in hepatocellular carcinoma.
Wei R; Feng OQ; Hui YZ; Huang X; Ping LS
Biosci Rep; 2023 Jul; 43(7):. PubMed ID: 37133437
[TBL] [Abstract] [Full Text] [Related]
9. Prediction of liver-Related Events With a Combination of liver Stiffness Measurements and Controlled Attenuation Parameters in Japanese Patients With Biopsy-Proven Non-alcoholic Fatty liver Disease.
Hayashi H; Kamada Y; Fujii H; Takahashi H; Oeda S; Iwaki M; Kawaguchi T; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Ultrasound Med Biol; 2023 Jul; 49(7):1658-1664. PubMed ID: 37120329
[TBL] [Abstract] [Full Text] [Related]
10. Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC.
Li S; Xia H; Wang Z; Zhang X; Song T; Li J; Xu L; Zhang N; Fan S; Li Q; Zhang Q; Ye Y; Lv J; Yue X; Lv H; Yu J; Lu W
Hepatology; 2023 Oct; 78(4):1079-1091. PubMed ID: 37114494
[TBL] [Abstract] [Full Text] [Related]
11. The Landscape of Early Growth Response Family Members 1-4 in Hepatocellular Carcinoma: Their Biological Roles and Diagnostic Utility.
Liang J; Wang J; Zeng J; Bai Z; Zheng Z; Zheng Y; Jiang F; Wu D
Dis Markers; 2022; 2022():3144742. PubMed ID: 36046377
[TBL] [Abstract] [Full Text] [Related]
12. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
[TBL] [Abstract] [Full Text] [Related]
13. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
Xu Q; Wang Y; Huang W
Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
[TBL] [Abstract] [Full Text] [Related]
14. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
[TBL] [Abstract] [Full Text] [Related]
15. clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology.
Strazzabosco M; Cortesi PA; Conti S; Okolicsanyi S; Rota M; Ciaccio A; Cozzolino P; Fornari C; Gemma M; Scalone L; Cesana G; Fabris L; Colledan M; Fagiuoli S; Ideo G; Zavaglia C; Perricone G; Munari LM; Mantovani LG; Belli LS
Liver Int; 2020 Jan; 40(1):60-73. PubMed ID: 31654608
[TBL] [Abstract] [Full Text] [Related]
16. Serum chitinase activity prognosticates metastasis of colorectal cancer.
Song Z; Chen E; Qian J; Xu J; Cao G; Zhou W; Wang F; Chen M; Xu D; Wang X; Hu X; Ju Z; Huang X; Cai X
BMC Cancer; 2019 Jun; 19(1):629. PubMed ID: 31238895
[TBL] [Abstract] [Full Text] [Related]
17. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma.
Xu X; Zhang HL; Liu QP; Sun SW; Zhang J; Zhu FP; Yang G; Yan X; Zhang YD; Liu XS
J Hepatol; 2019 Jun; 70(6):1133-1144. PubMed ID: 30876945
[TBL] [Abstract] [Full Text] [Related]
18. Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of liver Diseases.
Kanwal F; Tapper EB; Ho C; Asrani SK; Ovchinsky N; Poterucha J; Flores A; Ankoma-Sey V; Luxon B; Volk M
Hepatology; 2019 Apr; 69(4):1787-1797. PubMed ID: 30586188
[TBL] [Abstract] [Full Text] [Related]
19. Metabolic control of PPAR activity by aldehyde dehydrogenase regulates invasive cell behavior and predicts survival in hepatocellular and renal clear cell carcinoma.
Andrejeva D; Kugler JM; Nguyen HT; Malmendal A; Holm ML; Toft BG; Loya AC; Cohen SM
BMC Cancer; 2018 Nov; 18(1):1180. PubMed ID: 30486822
[TBL] [Abstract] [Full Text] [Related]
20. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
Calderaro J; Petitprez F; Becht E; Laurent A; Hirsch TZ; Rousseau B; Luciani A; Amaddeo G; Derman J; Charpy C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C
J Hepatol; 2019 Jan; 70(1):58-65. PubMed ID: 30213589
[TBL] [Abstract] [Full Text] [Related]
[Next]
